We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Stock Moves -4.04%: What You Should Know
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed at $1.90 in the latest trading session, marking a -4.04% move from the prior day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, lost 0.16%.
Shares of the maker of genetic analysis technology have appreciated by 53.49% over the course of the past month, outperforming the Medical sector's gain of 3.55%, and the S&P 500's gain of 1.16%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.16, showcasing a 5.88% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $39.84 million, reflecting a 0.33% fall from the equivalent quarter last year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.56 per share and revenue of $158.66 million. These results would represent year-over-year changes of +32.53% and +3.02%, respectively.
Investors should also note any recent changes to analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 7.18% increase. Pacific Biosciences of California is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacific Biosciences of California (PACB) Stock Moves -4.04%: What You Should Know
Pacific Biosciences of California (PACB - Free Report) closed at $1.90 in the latest trading session, marking a -4.04% move from the prior day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, lost 0.16%.
Shares of the maker of genetic analysis technology have appreciated by 53.49% over the course of the past month, outperforming the Medical sector's gain of 3.55%, and the S&P 500's gain of 1.16%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.16, showcasing a 5.88% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $39.84 million, reflecting a 0.33% fall from the equivalent quarter last year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.56 per share and revenue of $158.66 million. These results would represent year-over-year changes of +32.53% and +3.02%, respectively.
Investors should also note any recent changes to analyst estimates for Pacific Biosciences of California. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 7.18% increase. Pacific Biosciences of California is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.